Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Nasdaq Real Time Price USD

Astria Therapeutics, Inc. (ATXS)

Compare

5.15

-0.37

(-6.70%)

At close: April 3 at 4:00:02 PM EDT

5.02

-0.13

(-2.52%)

Pre-Market: 7:01:07 AM EDT

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria’s common stock on April 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

Business Wire yesterday

ATXS
-6.70%
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

BOSTON, March 11, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.

Business Wire 23 days ago

ATXS
-6.70%
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

BOSTON, February 27, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people living with hereditary angioedema (HAE). Navenibart has the potential to provide rapid and sustained HAE attack prevention with a very low treatment burden and administration every 3 months (Q3M) and every 6 months (Q6M).

Business Wire last month

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

BOSTON, February 25, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA.

Business Wire last month

ATXS
-6.70%
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Key Insights Astria Therapeutics' estimated fair value is US$6.81 based on 2 Stage Free Cash Flow to Equity Current...

Simply Wall St. last month

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

BOSTON, February 20, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025.

Business Wire last month

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

BOSTON, February 04, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 10:40am ET.

Business Wire last month

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

BOSTON, February 03, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215) in a poster displayed at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Scientific Session in Waimea, Hawaii from Sunday, February 9 through Thursday, February 13, 2025.

Business Wire last month

ATXS
-6.70%
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

BOSTON, January 23, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis (AD) and potentially other indications. The Phase 1a trial is inte

Business Wire 2 months ago

ATXS
-6.70%
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

BOSTON, January 13, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced its planned design of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people with hereditary angioedema (HAE), which will include both every 3- (Q3M) and every 6-month (Q6M) treatment arms with the primary analysis at 6 months. Global start-up activities are underway, and ALPHA-ORBIT is expected

Business Wire 2 months ago

ATXS
-6.70%
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

BOSTON, December 11, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These final results demonstrated reduction in the mean mon

Business Wire 3 months ago

ATXS
-6.70%
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

BOSTON, December 10, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist, the company is developing as a potential treatment for atopic dermatitis (AD) and potentially other indications. A Phase 1a trial of STAR-0310 in

Business Wire 3 months ago

ATXS
-6.70%
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

BOSTON, November 13, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.

Business Wire 4 months ago

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

BOSTON, November 13, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20th at 12:00pm GMT in London, UK.

Business Wire 4 months ago

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

BOSTON, October 30, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present interim quality of life results from the ALPHA-STAR trial of navenibart (STAR-0215) at the Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting in Banff, Alberta, Canada on November 7, 2024.

Business Wire 5 months ago

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

BOSTON, October 21, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Boston, Massachusetts on October 25, 2024.

Business Wire 5 months ago

ATXS
-6.70%
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 5 months ago

ATXS
-6.70%
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema

BOSTON, October 16, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to navenibart for the treatment of hereditary angioedema (HAE). Navenibart is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting attack prevention for HAE. Initial results from the

Business Wire 5 months ago

ATXS
-6.70%
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

BOSTON, September 30, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that navenibart (STAR-0215) has been granted Orphan Drug Designation for the treatment of hereditary angioedema (HAE) by the U.S. Food and Drug Administration (FDA). Navenibart is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting attack prevention for HAE. Initial re

Business Wire 5 months ago

ATXS
-6.70%
Astria Therapeutics to Present at Upcoming Global Angioedema Forum

BOSTON, September 27, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024.

Business Wire 6 months ago

ATXS
-6.70%

Performance Overview

Return	ATXS	S&P 500 (^GSPC)
YTD	-42.39%	-8.25%
1-Year	-57.44%	+3.55%
3-Year	-20.52%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Astria Therapeutics, Inc. (ATXS)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

Performance Overview